Press release
Verastem Oncology Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
New Data from Interim Analysis of Verastem Oncology’s RAMP 201 Trial Evaluating Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
About this update from Verastem, Inc.
[{"type":"text","content":"\nNew Data from Interim Analysis of Verastem Oncology’s RAMP 201 Trial Evaluating Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) to be Presented at the American Society of Clinical Oncology Annual Meeting\n\n\nStudies of Avutometinib Combinations in KRAS G12C Mutant Non-Small Lung Cancer, Pancreatic Cancer and Other RAS Pathway-Driven Cancers Advancing\n\n\nStrong Financial Position with Company Cash, Cash Equivalents, and Investments of $111.2 Million as of March 31, 2023\n\n\n BOSTON--(BUSINESS WIRE)--\nVerastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the first quarter ending March 31, 2023, and highlighted recent progress.\n\n\n“During the first quarter of this year, we announced the positive results from a planned interim analysis of Part A from our RAMP 201 trial in LGSOC. This, combined with a productive meeting with the FDA, has confirmed avutometinib and defactinib as the go-forward treatment regimen and reaffirmed our goal of filing for accelerated approval upon data maturity in the RAMP 201 trial and initiation of a confirmatory study,” said Brian Stuglik, Chief Executive Officer of Verastem Oncology. “We believe we are well positioned to deliver on our 2023 goals to initiate a confirmatory study of avutometinib and defactinib in recurrent LGSOC upon agreement with the FDA on study design, advance our KRAS G12C mutant NSCLC program and our frontline metastatic pancreatic cancer and progress our signal-finding, investigator-initiated trial program of combinations with avutometinib in additional RAS pathway-driven cancers with high unmet need.”\n\n\nFirst Quarter 2023 and Recent Highlights\n\n\nLow Grade Serous Ovarian Cancer (LGSOC)\n\n\n\nThe Company held a productive meeting with the FDA to discuss the encouraging results to date of the ongoing RAMP 201 LGSOC trial evaluating avutometinib ± defactinib among patients with recurrent LGSOC, confirmed the go-forward treatment regimen selection of avutometinib with defactinib based on a planned interim analysis with prespecified criteria and discussed the regulatory path forward.\n\n\n\n\nCompleted enrollment in the primary cohort of 72 patients in the combination arm of RAMP 201. Continued enrollment in the combination arm of R...